Satomi Shimura, Masahiro Ishima, Syo Nakajima, Toshitaka Fujii, Natsumi Himeno, Kentaro Ikeda, Jesus Izaguirre-Carbonell, Hiroshi Murata, Toshifumi Takeuchi, Shinji Kamisuki, Takahiro Suzuki, Kouji Kuramochi, Koichi Watashi, Susumu Kobayashi, Fumio Sugawara
Journal of the American Chemical Society 135 (50) 18949 - 18956 0002-7863 2013/12/18
[Refereed][Not invited] The first total synthesis of MA026 and the identification of its candidate target protein for anti-hepatitis C virus activity are presented. MA026, a novel lipocyclodepsipeptide isolated from the fermentation broth of Pseudomonas sp. RtIB026, consists of a cyclodepsipeptide, a chain peptide, and an N-terminal (R)-3-hydroxydecanoic acid. The first subunit, side chain 2, was prepared by coupling fatty acid moiety 4 with tripeptide 5. The key macrocyclization of the decadepsipeptide at l-Leu10-d-Gln11 provided the second subunit, cyclodepsipeptide 3. Late-stage condensation of the two key subunits and final deprotection afforded MA026. This convergent, flexible, solution-phase synthesis will be invaluable in generating MA026 derivatives for future structure-activity relationship studies. An infectious hepatitis C virus (HCV) cell culture assay revealed that MA026 suppresses HCV infection into host hepatocytes by inhibiting the entry process in a dose-dependent manner. Phage display screening followed by surface plasmon resonance (SPR) binding analyses identified claudin-1, an HCV entry receptor, as a candidate target protein of MA026. © 2013 American Chemical Society.